Moderna stock falls 12% after a 177% surge as investors weigh the intismeran cancer vaccine win, future demand, pricing and other cancer trials. (AP Photo/Bill Sikes, File)prnto
Moderna stock surged after its mRNA cancer vaccine showed positive Phase 3 results with Merck’s Keytruda, boosting hopes for a new melanoma treatment. (REUTERS/Dado Ruvic/Illustration/File Photo)